non-pharma add treatment for kids

How Dr. Getzelman Uses Genetic Assessments to Treat ADHD and Anxiety

Behavior and anxiety disorders among children are at an all-time high. A recent study revealed that attention deficit and hyperactivity disorder (ADHD) in kids has become more common over the past twenty years, with an increase from 6.1 percent in 1997 to 10.2 percent in 2016 – that’s over 6 million kids between 2-17 years! This is the “new normal,” but this is NOT normal.

ADD & ADHD: Does diet make a difference?

Although Attention Deficit Disorder (ADD) and Attention Deficit Hyperactivity Disorder (ADHD) are the most studied and diagnosed psychiatric disorders affecting children, there is still little consensus about the root causes of the disorders and their appropriate treatments.   According to the CDC, almost 10% of all children in the United States have received an attention deficit disorder diagnosis.  Treatment of the telltale symptoms of attention deficit and hyperactivity disorders (including chronic inattention, frequent distraction, impulsivity, fidgeting and difficulty controlling behavior) now accounts for a significant proportion of all drug use in children between the ages of 4-17.  In fact, there are now 17 different drugs approved to treat ADHD, contributing to a multibillion dollar ADHD industry.  However, a new study conducted by Radboud University Medical School and the ADHD Research Centre in the Netherlands1, presents compelling evidence that this blanket pharmacological approach to ADHD is misguided.  According to Dr. Lidy Piesser, the author of the study published in last month’s The Lancet medical journal, up to 64% of children who experience symptoms of ADHD might actually be experiencing sensitivity to foods.